An excellent op-ed ran this week in the San Francisco Chronicle, "Prescription mining raises millions for doctors' group." It highlights the American Medical Association's sale of physician profiles and data to drug companies, to help those drug companie

From pr.com: New Rap Song Takes Aim at Pharmaceuticals A new song called Pillagers by New Jersey rappers Sudden Death pokes fun at the pharmaceutical industry. The song spoofs the constant barrage of advertisements for new drugs and c

GlaxoSmithKline (NYSE:GSK) released its second quarter earnings statement on July 25, 2007. They reported that sales of over-the-counter alli hit $155 million since the drug's launch of June 14. This means that sales of alli have already exceeeded the $

Today, Pharmalot has an item about a dispute between AstraZeneca and Pharmac, New Zealand's drug buying agency, over a cardiovascular drug called Betaloc. Pharmac medical director Peter Moodie had this to say about AstraZeneca's patent tactics -- a quota

Zelnorm, a drug that was approved in 2002 for short-term treatment of women with "irritable bowel syndrome" and in 2004 for chronic constipation for men and women under age 65, was withdrawn from the market in March 2007 after studies showed an increased

In the wake of the drug safety scandals of the past few years (Vioxx, Celebrex, Paxil, etc), there were widespread predictions that Direct-to-Consumer Advertising (DTCA) of prescription drugs (TV commercials, magazine ads, etc) would become less prevalent

One of our goals here at the Prescription Access Litigation Blog is to highlight the good work being done by members of PAL's coalition of 130+ organizations. Below is an July 22 editorial from the Santa Rosa Press Democrat, written by Shirlee Zane, CEO

PAL member Breast Cancer Action issued the following statement yesterday. This raises some important issues -- about the use of prescription drugs to prevent cancer, about the environmental vs. individual factors in disease, and about how to deal with se

According to an increasing number of judges, the FDA should stick to regulating drugs for efficacy and safety and let the courts decide the scope of their own authority. A series of recent federal and state court opinions have rejected arguments that the